Media, Inc.

All Penny News: Soligenex Collects Another 2 Million Dollars from Government for GI Acute Radiation Syndrome Treatment


Mississauga, ON -- (SBWIRE) -- 08/01/2014 -- Media, Inc. ( announces its latest article titled “Soligenex Collects Another 2 Million Dollars from Government for GI Acute Radiation Syndrome Treatment.”

Companies mentioned in this article include Merck (NYSE:MRK) and Soligenex, Inc. (OTCQB:SNGX).

Article Excerpt:

As the name should imply, acute radiation syndrome, also called radiation toxicity or radiation sickness, is serious, sometimes dead serious. It’s caused when all or most of the body is exposed to a high dose of penetrating radiation reaching internal organs over a short period of time. Causes have included nuclear weapons, accidents involving nuclear reactors, radiotherapy mishaps and even space travel as astronauts can be exposed to different types of radiation. Symptoms usually present very quickly, ranging from loss of appetite to impaired central nervous system function, then subside only to present again at a later time, according to the Centers for Disease Control and Prevention. Even low exposure, doses below 1 gray (Gy) can cause symptoms, but as the radiation dose rises above 2 Gy, the prognosis starts to get bleaker. Exposure above 8 Gy usually spells death within two weeks, according to Merck (NYSE:MRK).

If there is a good thing related to acute radiation syndrome, it is that it isn’t seen very frequently, compared to other illnesses. To that point, though, it’s important that treatments are available when needed.

Soligenex, Inc. (OTCQB:SNGX) is developing a diversified portfolio of products divided into biotherapeutics and vaccines/biodefense categories. With that, the Princeton, New Jersey-based Company is addressing diseases and conditions, such as Crohn’s disease and oral mucositis, as well as vaccines for anthrax and ricin toxin. In the acute radiation syndrome (ARS) space, Soligenix is working on OrbeShield (oral beclomethasone 17,21 –dipropionate or “oral BDP”) for gastrointestinal ARS, one of the three classic ARS syndromes (the others being bone marrow syndrome and cardiovascular/central nervous system syndrome). Oral BDP is also being developed in the Soligenex portfolio as a treatment for gastrointestinal inflammation in pediatric Crohn’s disease, chronic Graft-versus-Host disease and acute radiation enteritis.

The full version of this article can be found at:

About is focused on the small-cap / penny stock market and has become a reputable name in the investment community. runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor. also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria looks for includes strong revenues, a seasoned management, innovative business plans, among many others. also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.

Investors are encouraged to subscribe to the FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here:

Contact: Media, Inc.
Peter Szafranski -- President
Phone: (905) 361-5680
Websites: /

Note: has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: